Literature DB >> 24229021

Favorable response after gemcitabine-radiotherapy for invasive pancreatic intraductal papillary mucinous neoplasm: a case report.

Takanori Ochiai1, Kimihiro Igari, Takaki Furuyama, Hiromitsu Ito, Yusuke Mitsunori, Arihiro Aihara, Yoichi Kumagai, Michio Iida, Hajime Odajima, Shinji Tanaka, Shigeki Arii, Shigeru Yamazaki.   

Abstract

The efficacy of chemoradiotherapy for invasive pancreatic ductal carcinoma derived from an intraductal papillary mucinous neoplasm (IPMN) has not been established. The subject of the present report was a 53-year-old man admitted for the treatment of IPMN. The tumor, located in the pancreatic body, was of the mixed type of IPMN, and it involved the branch duct, where it was 38 mm in diameter, and the main duct, where it was 6 mm in diameter. Distal pancreatectomy was performed and the postoperative course was uneventful; however, histopathologic diagnosis revealed invasive ductal carcinoma with a positive surgical margin in the pancreatic duct. Although total pancreatectomy was recommended, chemoradiotherapy (50.4-Gy irradiation and gemcitabine) was preferred by the patient. At 9-month follow up, computed tomography and magnetic resonance imaging showed a cystic mass at the surgical margin of the pancreas. Endoscopic ultrasonography showed a 44-mm cystic lesion with nodules in the remnant pancreas, on the basis of which he underwent total pancreatectomy. Pathologic examination of the resected specimen revealed absence of the epithelium at the surgical margin of the main pancreatic duct, and malignant cells were not detected.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24229021      PMCID: PMC3829061          DOI: 10.9738/INTSURG-D-13-00031.1

Source DB:  PubMed          Journal:  Int Surg        ISSN: 0020-8868


  26 in total

Review 1.  International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas.

Authors:  Masao Tanaka; Suresh Chari; Volkan Adsay; Carlos Fernandez-del Castillo; Massimo Falconi; Michio Shimizu; Koji Yamaguchi; Kenji Yamao; Seiki Matsuno
Journal:  Pancreatology       Date:  2006       Impact factor: 3.996

2.  Intraductal tubular neoplasms of the pancreas: histogenesis and differentiation.

Authors:  Takuma Tajiri; Genshu Tate; Tomoko Inagaki; Toshiaki Kunimura; Kazuaki Inoue; Toshiyuki Mitsuya; Makoto Yoshiba; Toshio Morohoshi
Journal:  Pancreas       Date:  2005-03       Impact factor: 3.327

Review 3.  Clinical aspects of intraductal papillary mucinous neoplasm of the pancreas.

Authors:  Masao Tanaka; Kiichiro Kobayashi; Kazuhiro Mizumoto; Koji Yamaguchi
Journal:  J Gastroenterol       Date:  2005-07       Impact factor: 7.527

Review 4.  Intraductal papillary mucinous tumors of the pancreas.

Authors:  Kevin C Conlon
Journal:  J Clin Oncol       Date:  2005-07-10       Impact factor: 44.544

5.  Intraductal papillary mucinous tumors of the pancreas comprise 2 clinical subtypes: differences in clinical characteristics and surgical management.

Authors:  M Kobari; S Egawa; K Shibuya; H Shimamura; M Sunamura; K Takeda; S Matsuno; T Furukawa
Journal:  Arch Surg       Date:  1999-10

6.  Adjuvant chemoradiotherapy after pancreatic resection for invasive carcinoma associated with intraductal papillary mucinous neoplasm of the pancreas.

Authors:  Michael J Swartz; Charles C Hsu; Timothy M Pawlik; Jordan Winter; Ralph H Hruban; Mehmet Guler; Richard D Schulick; John L Cameron; Daniel A Laheru; Christopher L Wolfgang; Joseph M Herman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-08-03       Impact factor: 7.038

Review 7.  Multidisciplinary approach to diagnosis and management of intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Dushyant V Sahani; Dana J Lin; Aradhana M Venkatesan; Nisha Sainani; Mari Mino-Kenudson; William R Brugge; Carlos Fernandez-Del-Castillo
Journal:  Clin Gastroenterol Hepatol       Date:  2008-11-13       Impact factor: 11.382

8.  Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study.

Authors:  B Chauffert; F Mornex; F Bonnetain; P Rougier; C Mariette; O Bouché; J F Bosset; T Aparicio; L Mineur; A Azzedine; P Hammel; J Butel; N Stremsdoerfer; P Maingon; L Bedenne
Journal:  Ann Oncol       Date:  2008-05-07       Impact factor: 32.976

9.  Mucin-hypersecreting tumors of the pancreas: assessing the grade of malignancy preoperatively.

Authors:  K Yamaguchi; Y Ogawa; K Chijiiwa; M Tanaka
Journal:  Am J Surg       Date:  1996-04       Impact factor: 2.565

10.  Ductectatic-type mucinous cystadenoma and cystadenocarcinoma of the human pancreas: a novel clinicopathological entity.

Authors:  A Yanagisawa; K Ohashi; M Hori; K Takagi; T Kitagawa; H Sugano; Y Kato
Journal:  Jpn J Cancer Res       Date:  1993-04
View more
  1 in total

1.  Intraductal papillary-mucinous carcinoma with portal vein tumor thrombus and multifocal liver metastasis: An autopsy case.

Authors:  Naohiro Matsushita; Akitoshi Douhara; Hirotsugu Ueno; Shohei Asada; Koji Murata; Koji Yanase; Masahiro Tsutsumi
Journal:  Mol Clin Oncol       Date:  2021-03-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.